Principal investigator: Prof. dr. P.A. (Pieter) Doevendans, Prof. dr. E. (Eva) van Rooij
Started: May 1st 2023

About the GEREMY project

The GEREMY project is funded by the European Health & Digital Executive Agency and aims to deliver the first cardiac gene therapy (GT) for treatment of rare inherited forms of arrhythmogenic cardiomyopathy (ACM), such as PLN- and PKP2-mutation induced ACM. These will serve as models for other inherited heart diseases and contribute directly to the portfolio of treatments for rare cardiac diseases.

Inherited cardiovascular conditions are a group of genetic disorders that primarily affect the heart. They include conditions such as cardiomyopathy, inherited electrical conditions called channelopathies and problems with the main blood vessel carrying blood from the heart, the aorta. They affect people of any age. If left untreated, some inherited heart conditions can be life-threatening. These inherited cardiac disorders cover a wide variety of relatively rare cardiac diseases, for which we don’t have any effective treatment or cure available. The GEREMY project would like to change that, and thus is THE approach to develop therapies for many (rare) inherited cardiac disorders including dilated and arrhythmogenic cardiomyopathy.


Consortium partners

  1. Netherlands Heart Institute, the Netherlands (Coordinator)
  2. Hubrecht Institute, the Netherlands
  3. University Medical Center Groningen, the Netherlands
  1. Technische Universität München, Germany
  2. University of Eastern Finland, Finland
  3. EUPATI, European Union
  1. PLN Foundation, the Netherlands
  2. KU Leuven, Belgium
  3. King’s College London, United Kingdom
  4. Exom group, Italy, Germany


Linked-in link:

Page Up